Novel hypoglycaemic agents: Considerations in patients with chronic kidney disease

Nephron - Clinical Practice

Volumn 126, Issue 1, 2014, Pages 14-18

  Game, Fran ^a  

^a DERBY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Drug treatment; Renal impairment; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; DRUG METABOLITE; NEW DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; MEGLITINIDE; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE BLOOD LEVEL; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

CHRONIC KIDNEY DISEASE; DRUG ACCUMULATION; GLYCEMIC CONTROL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; INSULIN TREATMENT; AGONISTS; ANTAGONISTS AND INHIBITORS; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GLUCOSE BLOOD LEVEL; METABOLISM; RENAL INSUFFICIENCY, CHRONIC;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; RECEPTORS, GLUCAGON; RENAL INSUFFICIENCY, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84892412800     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000357680     Document Type: Review

References (23)

1. Diabetes in the UK 2012. Key statistics on diabetes. Diabetes UK. http://www.diabetes. org.uk/Documents/Reports/Diabetes-in-the- UK-2012.pdf (accessed September 15, 2013).
2. SIGN. Management of Diabetes. Edinburgh, SIGN, 2010. http://www.sign.ac. uk/guidelines/ fulltext/116/index.html (accessed September 15, 2013).
3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
4. Nye HJ, Herrington W: Metformin: The safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract 2011; 118: 380-383.
5. The Royal College of Radiologists. Standards for intravenous contrast agent administration to adult patients, ed 2. 2010. http://www.rcr. ac.uk/docs/radiology/pdf/BFCR(10)4- Stand-contrast.pdf (accessed September 20, 2013).
6. National Institute for Health and Care Excellence. The management of type 2 diabetes (CG87). 2009. http://guidance.nice.org.uk/ cg87 (accessed October 10, 2013).
7. Repaglinide. Summary of product characteristics. www.medicines.org.uk/ EMC/medicine/ 18980/SPC/ (accessed September 15, 2013).
8. Nateglinide. Summary of product characteristics. www.medicines.org.uk/ emc/medicine/ 4622/SPC/ (accessed September 15, 2013).
9. Pioglitazone. Summary of product characteristics. http://www.medicines. org.uk/emc/ medicine/4236/SPC/ (accessed September 15, 2013).
10. Burgmaier M, Heinrich C, Marx N: Cardiovascular effects of GLP-1 and GLP-1 based therapies: implications for the cardiovascular continuum in diabetes? Diabetic Med 2013; 30: 289-299.
11. Dipeptidylpeptidase-4 inhibitors ('gliptins'): risk of acute pancreatitis. MRHA drug safety update. http://www.mhra.gov.uk/Safetyinformation/ DrugSafetyUpdate/CON185628 (accessed September 15, 2013).
12. Jose T, Inzucchi SE: Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res 2012; 9: 109-116.
13. Sitagliptin. Summary of product characteristics. www.medicines.org.uk/ emc/medicine/ 19609 (accessed September 16, 2013).
14. Vildagliptin. Summary of product characteristics. www.medicines.org.uk/ emc/medicine/ 20734 (accessed September 16, 2013).
15. Saxagliptin. Summary of product characteristics. www.medicines.org.uk/ emc/medicine/ 22315 (accessed September 16, 2013).
16. Linagliptin. Summary of product characteristics. www.medicines.org.uk/ EMC/medicine/ 25000 (accessed September 16, 2013).
17. Exenatide (Byetta): risk of severe pancreatitis and renal failure. http://www.mhra.gov.uk/ Safetyinformation/DrugSafetyUpdate/ CON088117 (accessed September 15, 2013).
18. Exenatide: Summary of product characteristics. http://www.medicines.org. uk/emc/medicine/ 19257/SPC/ (accessed September 15, 2013).
19. Liraglutide: Summary of product characteristics. http://www.medicines. org.uk/emc/medicine/ 21986/SPC (accessed September 15, 2013).
20. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al: Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel- group, open-label trial. Lancet 2010; 375: 1447-1456.
21. Rosenstock J, Raccah D, Korányi L, Maffei L, Boka G, Miossec P, Gerich JE: Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care 2013; 36: 2945-2951.
22. Lixisenatide: Summary of product characteristics. http://www.medicines. org.uk/emc/ medicine/27405/SPC/ (accessed September 15, 2013).
23. Dapagliflozin: Summary of product characteristics. http://www.medicines. org.uk/emc/ medicine/27188/SPC/ (accessed September 15, 2013).